PharmaLogic Holdings Corp., a CDMO and radiopharmacy solutions provider, has opened its new radiopharmaceutical production and research facility in Cincinnati, OH. 
 
The selection of Cincinnati for this facility highlights the organization’s commitment to increasing patient access to the most clinically relevant radiopharmaceuticals, many of which are not currently available to the greater community. The new production and laboratory space is equipped for PharmaLogic to expand current production, as well as focus additional efforts on research and development of novel compounds.
 
Steve Chilinski, CEO of PharmaLogic, said, “With this new cyclotron facility, we’re excited to be partnering with healthcare providers in the region to bring advanced radiopharmaceuticals to the patient community that will be the foundation for game-changing diagnosis and treatment of cancers, and neurological and heart diseases.”
 
“After years of meticulous planning and construction, we’re thrilled to unveil our advanced facility in Cincinnati,” said D. Scott Holbrook, Chief Strategy Officer and General Manager of PharmaLogic. “The impact of this facility extends far beyond expanding access to innovative radiopharmaceuticals for the greater Cincinnati community. The cutting-edge laboratory will empower PharmaLogic to advance a robust pipeline of novel radiopharmaceutical candidates, ultimately benefiting patients nationwide.”